June 27, 2016 05:54 AM EDTUpdated September 18, 11:49 PM
Bioregnum
Opinion

The Zer­houni rule: “Every com­pa­ny that ac­quires a plat­form com­pa­ny kills it.”

Why Medi­va­tion makes the per­fect biotech takeover tar­get for Sanofi

Last Jan­u­ary at the J.P. Mor­gan con­fab, I had a chance to sit …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times